Vaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial
Vaxart said it modified its BARDA funding contract via Advanced Technology International to match the current scope of its Phase 2b COVID-19 oral pill vaccine trial. Total available funding is now about $345 million, down ~$116 million after a BARDA partial termination reduced enrollment. The change releases ~$29 million to complete trial and exploratory analyses, enabling 12-month sentinel-cohort data in coming weeks and main-cohort data in 1H 2027.
How this was made
The 30-second read
Why it matters
The contract modification releases additional funding to continue the trial and advance data analysis, enabling unblinding and reporting of sentinel cohort 12-month data, with main cohort 12-month data targeted for H1 2027.
Market read
Fresh BARDA contract scope/funding update plus explicit data-reporting windows can shift near-term expectations for clinical milestone delivery.
What to watch
Unblinding/reporting is a process step, but the market will ultimately reprice on the actual 12-month safety/efficacy results; funding does not guarantee positive clinical endpoints.
Background
Vaxart’s Phase 2b COVID-19 oral pill vaccine trial received BARDA funding via Project NextGen and was partially terminated in Aug 2025, reducing participants and total funding.
Ticker impact
Vaxart modified its BARDA/ATI contract to release additional funding and enable unblinding/reporting of its Phase 2b COVID-19 oral pill trial data.
Near-term sentiment support as the company moves toward unblinding and data readouts; magnitude likely limited by prior participant reduction and OTC liquidity.
The article discloses a fresh contract modification, funding release amounts, and specific upcoming data timing (weeks for sentinel; H1 2027 for main), which can change perceived probability/timeline of clinical milestones.
Market effects
Reinforces ongoing government support for oral COVID-19 vaccine candidates and may modestly improve sentiment toward clinical-stage oral vaccine platforms.
Limited direct regional impact; primarily affects US biotech risk appetite for clinical-stage vaccine developers.
COVID-19 vaccine pipeline milestone timing can influence global investor sentiment toward next-gen oral vaccine approaches.
Counterpoint
The total award is lower and participants were cut after a BARDA partial termination, so the funding update may be more about managing scope than de-risking efficacy outcomes.
Key entities
- companyVaxart, Inc.
Clinical-stage biotech developing oral recombinant vaccines; subject of the BARDA contract modification and upcoming trial data releases.
- government_agencyBARDA
US Biomedical Advanced Research and Development Authority providing/adjusting funding for the trial under Project NextGen.
- contractorAdvanced Technology International (ATI)
Partner named in the contract through which BARDA funding is administered for trial continuation and data analysis.
